Egypts Central Nervous System diseases drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Egypt is an endemic area with Central nervous system (CNS) infections, which associated with high complications and death rates, so it is considered a medical emergency. In spite of emerging of new potent antibiotics and the availability of specific vaccination accompanied with improvement of medical care, morbidity rates accompanied with CNS infection remains unacceptably high.

Any infectious agents (bacteria, virus, fungus, or parasite) who can access the Central nervous system can produce specific clinical syndromes as meningitis, encephalitis, brain abscess, subdural empyema, and infectious thrombophlebitis. CNS infections carry high morbidity and mortality rates. septic meningitis can be lethal in 50% of untreated cases. Moreover, 1020% of the survivors develop permanent sequelae as brain damage, hearing loss, and learning incapacities, early clinical suspicion, appropriate investigations, and quick hospitalization for management can be lifesaving.



Market Drivers

Given that the geriatric population of Egypt is expected to expand by more than twice its present size, the risk of central nervous system diseases associated with old age, such as Alzheimer will also increase. Such a rise in the burden of the disease will drive the disease drug market in Egypt.

Further, reports of COVID-19 associated morbidities causing neurological complications have also emerged in regions of Egypt.

Prospective product launches for treating neurological disorders are anticipated to propel market growth over the forecast duration. These upcoming launches are expected to increase access to treatment in developing countries like Egypt.